• Deborah M. Milkowski
  • Rachelle A. Weiss
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Proliferation of endothelial cells is critical to the formation of new blood vessels. These cells, which form the innermost layer of the vasculature, are normally in the G0 phase of the cell cycle. They are able to respond to several different growth factors, and this response can result in neovascularization or angiogenesis. Angiogenesis is a normal physiologic component of growth, reproduction, and wound healing. It is also a pathogenic and critical component of tumor growth and metastasis, and it is this aspect of angiogenesis that the development of TNP-470 addresses.


Cervical Cancer Prostate Cancer Patient Lewis Lung Carcinoma Cervical Cancer Patient CoMBINATION Therapy Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348, 555–557.PubMedCrossRefGoogle Scholar
  2. 2.
    Kusaka, M., Sudo, K., Fujita, T., Marui, S., Itoh, F., Ingber, D., and Folkman, J. (1991) Potent antiangiogenic action ofAGM-1470: comparison of the fumagillin parent. Biochem. Biophys. Res. Commun. 174, 1070–1076.PubMedCrossRefGoogle Scholar
  3. 3.
    Kusaka, M., Sudo, K., Matsutani, E., Kozai, Y., Marui, S., Fujita, T., Ingber, D., and Folkman, J. (1994) Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer 69, 212–216.PubMedCrossRefGoogle Scholar
  4. 4.
    Ito, Y., Iwamoto, Y., Oshima, N., and Sugioka, Y. (1996) Quantitative evaluation of the effects of an angiogenesis inhibitor, TNP-470, by an in vivo tumor angiogenesis assay using basement membrane extracts. Cancer J. (France) 9, 95–100.Google Scholar
  5. 5.
    Antoine, N., Greimers, R., De Roanne, C., Kusaka, M., Heinen E. Simar, L. J., and Castronovo, V. (1994) AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the Gphase of the cell cycle. Cancer Res. 54, 2073–2076.PubMedGoogle Scholar
  6. 6.
    Yanase, T., Tamura, M., Fujita, K., Kodama, S., and Tanaka, K. (1993) Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res. 53, 2566–2570.Google Scholar
  7. 7.
    Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K., and Fujita, T. (1993) Angiogenesis inhibitor TNP470 (AGM-1470) potentially inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res. 53, 5233–5236.PubMedGoogle Scholar
  8. 8.
    Takamiya, Y., Brem, H., Ojeifo, J., Mineta, T., and Martuza, R. L. (1994) AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34, 869–875.CrossRefGoogle Scholar
  9. 9.
    Antoine, N., Daukandt, M., Heinen, E., Simar, L. J., and Castronovo, V. (1996) In vitro and in vivo stimulation of murine immune system by AGM0–1470, a potent angiogenesis inhibitor. Am J. Pathol. 148, 393–398.Google Scholar
  10. 10.
    Antoine, N., Daukandt, M., Locigno, R., Heinen, E., Simar, L. J., and Castronovo, V. (1996) Potent antioinhibin AGM-1470 stimulates normal but not tumor lymphocytes. Tumor (Italy) 82, 27–30.Google Scholar
  11. 11.
    Isobe, N., Vozumi, T., Kuriso K., and Kawamoto, K. (1996) Antitumor effect of TNP-470 on glial tumors transplanted in rats. Anticancer Res. 16, 71–76.PubMedGoogle Scholar
  12. 12.
    Yanase, T., Tamura, M., Fujita, K., Kodama, S., and Tanaka, K. (1993) Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res. 53, 2566–2570.Google Scholar
  13. 13.
    Schoof, D. D., Obando, J. A., Cusack, J. C., Jr., Goedegeburre, P. S., Brem, H., and Eberlein, T. J. (1993) Influence of angiogenesis inhibitor AGM-1470 on immune system status and tumor growth in vitro. Int. J. Cancer 55, 603–635.Google Scholar
  14. 14.
    Nagabuchi, E., Vander Kolk, W. E., Une, Y., and Ziegler, M. M. (1997) TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J. Ped Surg. 32, 287–293.CrossRefGoogle Scholar
  15. 15.
    Kamei, S., Okada, H., Inove, Y., Yoshioka, T., Ogawa, Y., and Toguchi, H. (1993) Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J. Pharmacol. Exp. Ther. 264, 469–474.PubMedGoogle Scholar
  16. 16.
    Yanai, S., Okada, H., Misaki, M., Saito, K., Kuge, Y., Ogawa Y., and Toguchi, H. (1994) Antitumor activity of a medium-chain triglyceride solution of the angiogenesis inhibitor TNP-470 (AGM-1470) when administered via the hepatic artery to rats bearing Walker 256 carcinosarcoma in the liver. J. Pharmacol. Exp. Ther. 271, 1267–1273.PubMedGoogle Scholar
  17. 17.
    Tanaka, Y., Kawamata, H., Fujimoto, K., and Oyasu, R. (1997) Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J. Urol. 157, 683–688.PubMedCrossRefGoogle Scholar
  18. 18.
    Yamaoka, M., Yamamoto, T., Masaki, T., Ikeyama, S., Sudo, K., and Fujita, K. (1993) Inhibition of tumor growth and metastasis of rodent tumor by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) funagillol. (TNP-470, AGM-1470). Cancer Res. 53, 4262–4267.PubMedGoogle Scholar
  19. 19.
    Ahmed, M. H., Konno, H., Nahar, L., Tanaka, T., Naito, Y., Nakamora, S., and Baba, S. (1996) Angiogenesis inhibitor TNP-470 (AGM-1470) improves long term survival of rats with liver metastasis. J. Surg. Res. 64, 35–41.PubMedCrossRefGoogle Scholar
  20. 20.
    Futami,H.Iseki,H.Egawa, S., Koyama, K., and Yamaguchi, K. (1996) Inhibition of lymphatic metastasis in a syngeneic rat fibrosarcoma model by an angiogenesis inhibitor (AGM-1470). Invasion Metastasis 16 73–82.Google Scholar
  21. 21.
    Kano, Y., Tamazaki, R., Shirai, Y., and Kakuta, H. (1996) Effects ofan injection ofanti-bFGF antibody (3H3) and angiogenesis inhibitor (TNP470) on mouse syngeneic solid tumor (NR-SI). Biotherapy, 10, 530–532.Google Scholar
  22. 22.
    Toi, M., Yamaoto, Y., Imazawa, T., Takanayagi, T., Akutsu, K., and Tominaga, T. (1993) Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. Int. J. Oncol. 3, 525–528.PubMedGoogle Scholar
  23. 23.
    Toi, M., Yamamoto, Y., Imazawa, T., Takanayagi, T., Akutsu, K., and Tominaga, T. (1995) Combination effect of an angiogenesis inhibitor AGM-1470 with 5’ deoxy-5-fluorouridine, and with hormonal drugs in DMBA-induced rat mammary tumors. Oncol. Rep. 2, 793–798.PubMedGoogle Scholar
  24. 24.
    Teicher, B. A., Emi, Y., Kakeji, Y., and Northey, D. (1996) TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Eur. J. Cancer 32A, 2461–2466.CrossRefGoogle Scholar
  25. 25.
    Kato, T., Sato, K., Kakinuma, H., and Matsuda, Y. (1994) Enhanced suppression of tumor growth by combination ofangiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res. 54, 5143–5147.PubMedGoogle Scholar
  26. 26.
    Melesky, S. E., Zhang, L., Trock, B. J., Kharbanda, S., Liu, Y., Gottardis, M. M., Lippman, M. E., and Kern, E. G. (1996) Effects of AGM-1470 and pentosan polysulfate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. Br. J. Cancer 73, 1053–1062.CrossRefGoogle Scholar
  27. 27.
    Yano, T., Tanase, M., Watanabe, A., Sawada, H., Yamada, Y., Shino, Y., Nakano, H., and Ohnishi, T. (1995) Enhancement effect of an anti-angiogenic agent, TNP-470, on hyperthermia-induced growth suppression of human esophageal and gastric cancers transplantable to nude mice. Anticancer Res. 15, 1355–1358.PubMedGoogle Scholar
  28. 28.
    Teicher, B. A., Holden, S. A., Dupuis, N. P., Kakeji, Y., Ikebe, M., Emi, Y., and Goff, D. (1995) Potentiation of cytotoxic therapies by TNP-470 and minoycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res. Treat. 36, 227–236.PubMedCrossRefGoogle Scholar
  29. 29.
    Teicher, B. A., Holden, S. A., Ara, G., Korbut, T., and Menon, K. (1996) Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in Lewis lung carcinoma. Cancer Chemother. Pharmocol. 38, 169–177.CrossRefGoogle Scholar
  30. 30.
    Parangi, S., O’Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., and Hanahan, D. (1996) Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 93, 2002–2007.PubMedCrossRefGoogle Scholar
  31. 31.
    Teicher B. A., Dupuis, N. P., Robinson, M. F., Emi, Y., and Goff, D. A. (1995) Anti-angiogenesis treatment (TNP-470 minocycline) increases tissue levels ofanticancer drugs in mice bearing Lewis lung carcinoma. Oncol. Res. 7, 237–243.PubMedGoogle Scholar
  32. 32.
    Devineni, D., Klein-Szanto, A., and Gallo, J. (1996) Uptake of temozolamide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res. 56, 1983–1987.PubMedGoogle Scholar
  33. 33.
    Masuoka, S. (1996) Anti-tumor effects of an angiogenesis inhibitor, TNP-470 (AGM-1470) alone and in combination with cisplatinum, and changes in serum copper levels in liver cancer bearing rats. Hokkaido J. Med. Sci. 71, 69–80.Google Scholar
  34. 34.
    Dike, L. and Ingber, D. (1992) Inhibition of cell cycle progression in capillary endothelial cells by TNP470. Takeda Report N-5–113.Google Scholar
  35. 35.
    Abe, J., Zhou, W., Takuwa, N., Taguchi, J., Kurokawa, K., Kumada, M., and Takuwa, Y. (1994) A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation ofcyclin-dependent kinases and phosporylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res. 54, 3407–3412.PubMedGoogle Scholar
  36. 36.
    Maier J. A. M., Delia, D., Thorpe, P. E., and Gasparini, G. (1997) In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. AntiCancer Drugs 8, 238–244.Google Scholar
  37. 37.
    Budson, A. E., Ko, L., Brasel, C., and Brickoff, J. (1996) Angiogenesis inhibitor AGM-1470 selectively increases E-selectin. Biochem. Biophys. Res. Commun. 225, 141–145.PubMedCrossRefGoogle Scholar
  38. 38.
    Koyama, H., Nishizawa, Y., Hosoi, M., Fukumoto, S., Kogawa, K., Shioi, A., and Morii, H. (1996) Fumagillin analog TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-1. Circ. Res. 79, 757–764.PubMedCrossRefGoogle Scholar
  39. 39.
    Kano, Y., Yamazaki, R., Shirai, Y., and Kakuta, H. (1996) Effects of an injection of anti-bFGF antibody (3H3) and angiogenesis inhibitor (TNP-470) on mouse syngeneic solid tumor (NR-SI). Biotherapy (Japanese) 10, 530–532.Google Scholar
  40. 40.
    Fujimoto, J., Hori, M., Ichigo, S., Hirose, R., Sakaguchi, H., and Tamaya, T. (1997) Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacety-carbamoyl) fumagillol (TNP-470, AGM-1470). CancerLett. 113, 187–194.Google Scholar
  41. 41.
    Kondo, M. (1996) Inhibitory effect of angiogenesis inhibitor TNP-470 in proliferation and liver metastasis of colon-26 cells in vitro and in vivo. Nippon Daicho-Koumonbio Koishi (Japanese) 49, 101–111.CrossRefGoogle Scholar
  42. 42.
    Sin, Y., Meng, L., Wang M. Q. W., Wen, J. J., Bornmann, W. G., and Crews, C. M. (1997) The antiangiogenic fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA 94, 6099–6103.PubMedCrossRefGoogle Scholar
  43. 43.
    Daha, B., Chakrabarti, D., Roy, A., and Gupta, N. K. (1988) Roles of a 67-kDa polypeptide in reversal of protein synthesis inhibition in heme-defiiciant reticulocyte lysate. Proc. Natl. Acad. Sci. USA 85, 3324–3328.CrossRefGoogle Scholar
  44. 44.
    Wu, S., Rehemtulla, A., Gupta, N. K., and Kaufmann, R. J. (1996) Eukaryotic translation initiation factor-2-associated 67-kDa glycoprotein partially reverses protein synthesis inhibition by activated double-stranded RNA-dependent protein kinase in intact cells. Biochemistry 35, 8275–8280.PubMedCrossRefGoogle Scholar
  45. 45.
    Peseckis, S. M., Drichaite, I., and Resh, M. D. (1993) Iodinated fatty acids as probes for myristate processing and function. J. Biol. Chem. 268, 5107–5114.PubMedGoogle Scholar
  46. 46.
    Bachmair A. Finely, D., and Varshavsky, A. (1986) In vivo half-life of a protein is a function of its aminoterminal residue. Science 234, 179–186.Google Scholar
  47. 47.
    Dezube, B. J., Von Roenn, J. H., Holden-Wiltse, J., Cheung, T. W., Remick, S. C., Cooley, T. P., et al. (1997) Fumagillin analog (TNP-470) in the treatment of Kaposi’s sarcoma: A Phase I AIDS Clinical Trial Group Study. J. Clin. Oncol. submitted.Google Scholar
  48. 48.
    Levy, T., Kudelka, A., Vershraegen, C. F., Edwards, C. L., Freedman, R. S., Kaplan, A., et al. (1996) A Phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Proc. Am. Assoc. Cancer Res. 37, 166A (abstract)Google Scholar
  49. 49.
    Kudelka, A. P., Levy, T., Verschraegen, C. F., Edwards, C. L., Piamsomboon, S., Termrungruanglert, W., et al. (1997) A Phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res. submitted.Google Scholar
  50. 50.
    Bhargava, P., Marshall, J., Rizvi, N., Dahut, W., Yoe, J., Figueira, M., et al. (1997) Study of TNP-470 in patients with advanced cancer. Am. Assoc. Cancer Res 38, 1489A.Google Scholar
  51. 51.
    Holmgren, L., O’Reilly, M. S., and Folkman, J. (1997) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1, 149–153.Google Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Deborah M. Milkowski
  • Rachelle A. Weiss

There are no affiliations available

Personalised recommendations